Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Comparison of Antibody Responses Following Vaccination with AstraZeneca and Sinopharm

Thu May 23 03:26:45 2024

(2022) Comparison of Antibody Responses Following Vaccination with AstraZeneca and Sinopharm. Iranian Journal of Immunology. pp. 321-329. ISSN 17351383 (ISSN)

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2. Methods: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique. Results: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, P<0.0001) and the second dose (10.36 μg/ml vs. 4.88 μg/ml, P<0.0001). Conclusions: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic. © 2022, Shiraz University of Medical Sciences. All rights reserved.

Item Type: Article
Creators:
CreatorsEmail
Anvari, E.UNSPECIFIED
Talepoor, A. G.UNSPECIFIED
Vakili, M. E.UNSPECIFIED
Karami, N.UNSPECIFIED
Ataollahi, M. R.UNSPECIFIED
Najafi, G.UNSPECIFIED
Kabalitz, D.UNSPECIFIED
Ahmadi, I.UNSPECIFIED
Kalantar, K.UNSPECIFIED
Keywords: COVID-19 Neutralizing antibody Oxford-AstraZeneca Sinopharm Vaccine immunoglobulin G virus antibody virus vaccine antibody production human pandemic prevention and control vaccination Antibodies, Neutralizing Antibodies, Viral Antibody Formation ChAdOx1 nCoV-19 Humans Pandemics SARS-CoV-2 Viral Vaccines
Divisions:
Page Range: pp. 321-329
Journal or Publication Title: Iranian Journal of Immunology
Journal Index: Scopus
Volume: 19
Number: 3
Identification Number: https://doi.org/10.22034/iji.2022.94298.2300
ISSN: 17351383 (ISSN)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4104

Actions (login required)

View Item View Item